Video: Interview With Ovid Therapeutics' Jeremy Levin
The former Teva CEO now heads up neuroscience-focused Ovid. At BioPharm America, he discussed the trend of execs moving from large pharmas to smaller companies as well as the business strategy for Ovid.
You may also be interested in...
Formerly an executive with Genzyme and TetraLogic, Sarah Frew of the University of Pennsylvania's Center for Innovation spoke with "The Pink Sheet" at BioPharm America about the deal-making atmosphere between academia and private industry.
Since his departure from Sanofi, Viehbacher has taken on a significant role in venture capital; at the recent BioPharm America conference, he spoke about his company's business model and goals, as well as the trend of pharma execs moving to smaller companies.
In an interview at the recent BioPharm America conference, Shah explains the role that BioMotiv, a self-described accelerator, plays in advancing academic research into private-sector biopharma companies.